pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
86
stories
19h
Moderna maintains 10% growth target despite Phase 3 norovirus miss
biospace
2d
GSK pens $110M biological datasets pact with AI biotech Relation
fiercebiotech
2d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
2d
GSK cost-cutting plan includes global layoffs
biospace
3d
Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
fiercebiotech
3d
GSK shares rise as $2.5B cost-cutting plan unveiled
biospace
3d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
4d
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
5d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
7d
Anthropic’s life science plans; Novartis CEO on China deals; and more
endpoints
8d
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
9d
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
9d
Novartis scraps mid-stage radiopharma asset as Pluvicto soars
biospace
9d
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
10d
AI data becomes sticking point in biopharma dealmaking
biospace
10d
Agios scraps sickle cell drug
biopharma dive
10d
Novartis CEO says latest China deals are just following the science
endpoints
10d
Novartis climbs on upbeat drug sales as key readouts loom
biopharma dive
10d
STAT+: Anthropic deepens work with rare disease drugs
stat
10d
Novartis stays 'geography-agnostic' in dealmaking amid flurry of China deals
biospace
10d
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
11d
Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
fiercebiotech
11d
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
biopharma dive
11d
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
biospace
12d
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
14d
Jasper gets a lifeline in merger with immune drugmaker Kira
biopharma dive
14d
Dimerix buys a kidney injury drug; Arpeggio appears to be winding down
endpoints
14d
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
biopharma dive
15d
Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador
fiercebiotech
16d
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
biospace
← prev
page 1 of 3
next →
